Neuroblastoma mRNAs predict outcome in children with stage 4 neuroblastoma: A European HR-NBL1/SIOPEN study

Journal of Clinical Oncology

Volumn 32, Issue 10, 2014, Pages 1074-1083

  Viprey, Virginie F ^a   Gregory, Walter M ^b   Corrias, Maria V ^e   Tchirkov, Andrei ^g   Swerts, Katrien ⁱ   Vicha, Ales ^j   Dallorso, Sandro ^e   Brock, Penelope ^c   Luksch, Roberto ^f   Valteau Couanet, Dominique ^h   Papadakis, Vassilios ^k   Laureys, Genevieve ⁱ   Pearson, Andrew D ^d   Ladenstein, Ruth ^l   Burchill, Susan A ^a  

^a ST JAMES S UNIVERSITY HOSPITAL   (United Kingdom)

^b UNIVERSITY OF LEEDS   (United Kingdom)

^c GREAT ORMOND STREET HOSPITAL   (United Kingdom)

^d INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^e G GASLINI INSTITUTE   (Italy)

^f NATIONAL CANCER INSTITUTE   (Italy)

^g UNIVERSITY HOSPITAL OF CLERMONT FERRAND   (France)

^h INSTITUT GUSTAVE ROUSSY   (France)

ⁱ GHENT UNIVERSITY HOSPITAL   (Belgium)

^j UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^k AGHIA SOPHIA CHILDREN S HOSPITAL   (Greece)

^l ST ANNA CHILDREN S HOSPITAL   (Austria)

more..

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOUBLECORTIN; ETOPOSIDE; MESSENGER RNA; PAIRED LIKE HOMEOBOX 2B; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; VINCRISTINE; ANTINEOPLASTIC AGENT; DOUBLECORTIN PROTEIN; HOMEODOMAIN PROTEIN; MICROTUBULE ASSOCIATED PROTEIN; NBPHOX PROTEIN; NEUROPEPTIDE; TRANSCRIPTION FACTOR; TUMOR MARKER;

ARTICLE; BONE MARROW BIOPSY; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL (TOPIC); EVENT FREE SURVIVAL; HUMAN; HUMAN TISSUE; INFANT; MAJOR CLINICAL STUDY; NEUROBLASTOMA; OVERALL SURVIVAL; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; ADOLESCENT; BLOOD; BONE MARROW; COMPUTER SIMULATION; DISEASE FREE SURVIVAL; GENETICS; INDUCTION CHEMOTHERAPY; KAPLAN MEIER METHOD; METABOLISM; PREDICTIVE VALUE; PRESCHOOL CHILD; PROPORTIONAL HAZARDS MODEL; SURVIVAL RATE;

ADOLESCENT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE MARROW; CARBOPLATIN; CHILD; CHILD, PRESCHOOL; CISPLATIN; COMPUTER SIMULATION; CYCLOPHOSPHAMIDE; DISEASE-FREE SURVIVAL; ETOPOSIDE; HOMEODOMAIN PROTEINS; HUMANS; INDUCTION CHEMOTHERAPY; INFANT; KAPLAN-MEIER ESTIMATE; MICROTUBULE-ASSOCIATED PROTEINS; NEUROBLASTOMA; NEUROPEPTIDES; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SURVIVAL RATE; TRANSCRIPTION FACTORS; TUMOR MARKERS, BIOLOGICAL; TYROSINE 3-MONOOXYGENASE; VINCRISTINE;

EID: 84901688170     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.53.3604     Document Type: Article

References (34)

1. Matthay KK, Villablanca JG, Seeger RC, et al: Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid: Children's Cancer Group. N Engl J Med 341:1165-1173, 1999 (Pubitemid 29480654)
2. London WB, Castleberry RP, Matthay KK, et al: Evidence for an age cutoff greater than 365 days for neuroblastoma risk group stratification in the Children's Oncology Group. J Clin Oncol 23:6459-6465, 2005 (Pubitemid 46190236)
3. Monclair T, Brodeur GM, Ambros PF, et al: The International Neuroblastoma Risk Group (INRG) staging system: An INRG Task Force report. J Clin Oncol 27:298-303, 2009
4. Cohn SL, Pearson AD, London WB, et al: The International Neuroblastoma Risk Group (INRG) classification system: An INRG Task Force report. J Clin Oncol 27:289-297, 2009
5. Ambros PF, Ambros IM, Brodeur GM, et al: International consensus for neuroblastoma molecular diagnostics: Report from the International Neuroblastoma Risk Group (INRG) Biology Committee. Br J Cancer 100:1471-1482, 2009
6. Burchill SA, Selby PJ: Molecular detection of low-level disease in patients with cancer. J Pathol 190:6-14, 2000 (Pubitemid 30053347)
7. Burchill SA, Lewis IJ, Abrams KR, et al: Circulating neuroblastoma cells detected by reverse transcriptase polymerase chain reaction for tyrosine hydroxylase mRNA are an independent poor prognostic indicator in stage 4 neuroblastoma in children over 1 year. J Clin Oncol 19:1795-1801, 2001 (Pubitemid 32230882)
8. Horibe K, Fukuda M, Miyajima Y, et al: Outcome prediction by molecular detection of minimal residual disease in bone marrow for advanced neuroblastoma. Med Pediatr Oncol 36:203-204, 2001
9. Tchirkov A, Paillard C, Halle P, et al: Significance of molecular quantification of minimal residual disease in metastatic neuroblastoma. J Hematother Stem Cell Res 12:435-442, 2003 (Pubitemid 36993431)
10. Cheung IY, Lo Piccolo MS, Kushner BH, et al: Early molecular response of marrow disease to biologic therapy is highly prognostic in neuroblastoma. J Clin Oncol 21:3853-3858, 2003 (Pubitemid 46606241)
11. Pession A, Libri V, Sartini R, et al: Real-time RT-PCR of tyrosine hydroxylase to detect bone marrow involvement in advanced neuroblastoma. Oncol Rep 10:357-362, 2003
12. Corrias MV, Faulkner LB, Pistorio A, et al: Detection of neuroblastoma cells in bone marrow and peripheral blood by different techniques: Accuracy and relationship with clinical features of patients. Clin Cancer Res 10:7978-7985, 2004 (Pubitemid 39587539)
13. Parareda A, Gallego S, Roma J, et al: Prognostic impact of the detection of microcirculating tumor cells by a real-time RT-PCR assay of tyrosine hydroxylase in patients with advanced neuroblastoma. Oncol Rep 14:1021-1027, 2005
14. Träger C, Vernby A, Kullman A, et al: mRNAs of tyrosine hydroxylase and dopa decarboxylase but not of GD2 synthase are specific for neuroblastoma minimal disease and predicts outcome for children with high-risk disease when measured at diagnosis. Int J Cancer 123:2849-2855, 2008
15. Stutterheim J, Zappeij-Kannegieter L, Versteeg R, et al: The prognostic value of fast molecular response of marrow disease in patients aged over 1 year with stage 4 neuroblastoma. Eur J Cancer 47:1193-1202, 2011
16. Burchill SA: Micrometastases in neuroblastoma: Are they clinically important? J Clin Pathol 57:14-20, 2004
17. Viprey VF, Corrias MV, Kagedal B, et al: Standardisation of operating procedures for the detection of minimal disease by QRT-PCR in children with neuroblastoma: Quality assurance on behalf of SIOPEN-R-NET. Eur J Cancer 43:341-350, 2007 (Pubitemid 46123979)
18. Kågedal B: Detecting minimal residual disease in neuroblastoma: Still a ways to go. Clin Chem 55:1268-1270, 2009
19. Viprey VF, Lastowska MA, Corrias MV, et al: Minimal disease monitoring by QRT-PCR: Guidelines for identification and systematic validation of molecular markers prior to evaluation in prospective clinical trials. J Pathol 216:245-252, 2008
20. Ladenstein R, Valteau-Couanet D, Brock P, et al: Randomized trial of prophylactic granulocyte colony-stimulating factor during rapid COJEC induction in pediatric patients with high-risk neuroblastoma: The European HR-NBL1/SIOPEN study. J Clin Oncol 28:3516-3524, 2010
21. Pearson AD, Pinkerton CR, Lewis IJ, et al: Highdose rapid and standard induction chemotherapy for patients aged over 1 year with stage 4 neuroblastoma: A randomised trial. Lancet Oncol 9:247-256, 2008 (Pubitemid 351722944)
22. Brodeur GM, Pritchard J, Berthold F, et al: Revisions of the international criteria for neuroblastoma diagnosis, staging, and response to treatment. J Clin Oncol 11:1466-1477, 1993 (Pubitemid 23228250)
23. Gelman A, Hill J: Missing-data imputation, in Data Analysis Using Regression and Multilevel/Hierarchical Models. Cambridge, United Kingdom, Cambridge University Press, 2007, pp 529-543
24. Royston P, Altman DG: Regression using fractional polynomials of continuous covariates: Parsimonious parametric modelling (with discussion). Appl Stat 43:429-467, 1994
25. Altman DG, Royston P: The cost of dichotomising continuous variables. BMJ 332:1080, 2006 (Pubitemid 44365491)
26. Yanik GA, Parisi MT, Shulkin BL, et al: Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: A report from the Children's Oncology Group. J Nucl Med 54:541-548, 2013
27. Corrias MV, Haupt R, Carlini B, et al: Multiple target molecular monitoring in bone marrow and peripheral blood samples from patients with localized neuroblastoma and healthy donors. Pediatr Blood Cancer 58:43-49, 2012
28. Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, et al: PHOX2B is a novel and specific marker for minimal residual disease testing in neuroblastoma. J Clin Oncol 26:5443-5449, 2008
29. Cheung IY, Feng Y, Gerald W, et al: Exploiting gene expression profiling to identify novel minimal residual disease markers of neuroblastoma. Clin Cancer Res 14:7020-7027, 2008
30. Stutterheim J, Gerritsen A, Zappeij-Kannegieter L, et al: Detecting minimal residual disease in neuroblastoma: The superiority of a panel of real-time quantitative PCR markers. Clin Chem 55:1316-1326, 2009
31. Maris JM: Recent advances in neuroblastoma. N Engl J Med 362:2202-2211, 2010
32. Vermeulen J, De Preter K, Naranjo A, et al: Predicting outcomes for children with neuroblastoma using a multigene-expression signature: A retrospective SIOPEN/COG/GPOH study. Lancet Oncol 10:663-771, 2009
33. Oberthuer A, Hero B, Berthold F, et al: Prognostic impact of gene expression-based classification for neuroblastoma. J Clin Oncol 28:3506-3511, 2010
34. Beiske K, Burchill SA, Cheung IY, et al: Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: Recommendations by the International Neuroblastoma Risk Group Task Force. Br J Cancer 100:1627-1637, 2009